Japan, March 11 -- NEC Corporation has announced that it will partner with the Nagasaki University DEJIMA Infectious Disease Research Alliance (Director: Prof. Kouichi Morita) for a research and development (R&D) project with support from the Coalition for Epidemic Preparedness Innovations (CEPI).The CEPI funding, of up to 750 million JPY, will facilitate the composition optimization of "Nanoball," a proprietary vaccine particle covered under Nagasaki University's intellectual property, and the application of NEC OncoImmunity (NOI)'s artificial intelligence (AI) for the analysis of candidate proteins for a Severe Fever with Thrombocytopenia Syndrome (SFTS) vaccine.The emerging tick-borne virus, a member of the new windowPhenuivirus family, ...